|Other Names||Metabotropic glutamate receptor 2, mGluR2, GRM2, GPRC1B, MGLUR2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6342a was selected from the C-term region of human GPRC1B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.|
|Cellular Location||Cell membrane; Multi-pass membrane protein. Cell junction, synapse. Cell projection, dendrite|
|Tissue Location||Detected in brain cortex (at protein level). Widely expressed in different regions of the adult brain as well as in fetal brain.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 (also known as GPRC1B) and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. The activity of GRM2 is mediated by a G-protein that inhibits adenylate cyclase activity. This protein may mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.
Anneser, J.M., et al., J. Neuropathol. Exp. Neurol. 63(8):831-840 (2004).Dietrich, D., et al., Neuropharmacology 42(3):297-305 (2002).Krampfl, K., et al., Eur. J. Neurosci. 15(1):51-62 (2002).Marti, S.B., et al., Am. J. Med. Genet. 114(1):12-14 (2002).Malherbe, P., et al., Mol. Pharmacol. 60(5):944-954 (2001).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.